Top

Published in:

01-03-2020 | Metastasis | Original Article

Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry

Authors: Nehara Begum, Sebastian Maasberg, Andreas Pascher, Ursula Plöckinger, Thomas M. Gress, Christine Wurst, Frank Weber, Andreas Raffel, Markus Krausch, Katharina Holzer, Detlef K. Bartsch, Thomas J. Musholt, Tobias Keck, Martin Anlauf, Anja Rinke, Ulrich-Frank Pape, Peter E. Goretzki, On behalf of the German NET-Registry

Published in: Langenbeck's Archives of Surgery | Issue 2/2020

Abstract

Background

Neuroendocrine neoplasia (NEN) are rare and heterogenous tumours. Few data exist on the impact of surgical therapy.

Materials and methods

This is a retrospective analysis of prospectively collected data of gastroenteropancreatic NEN in the German NET-Registry (1999–2012). It focuses on patients without distant metastases (limited disease, LD, stage I–IIIB).

Results

Data of 2239 patients with NEN were recorded. Median age was 59 years, the gender ratio was 1:1.3 (f:m). A total of 986 patients (44%) had LD, and the 5-year survival rate (5 years) was 77% for all and 90% for patients with LD. A total of 1635 patients (73%) received a surgical therapy (1st to 6th line); the 5 and 10 ysr were 83/65% after and 59/35% without surgery for all patients (p < .001). The resection margins in the LD patients were 76%, 16%, and 3% for R0, R1 and R2, respectively. The 10 ysr was 84%, 59% and 42% for R0, R1 and R2 resections, respectively (p = .021 R0/R1, p < .001 R0/R2). The R0 resection rate was 75% for G1/G2 NET and 67% for G3 NEC.

Conclusion

The rate of complete tumour resection (R0) in LD is independent of tumour grading, and R0 resection is the key determinant of long-term survival, as demonstrated by the 10 ysr. of 84%. All NEN patients with limited disease should be considered for operation, if possible, as the best 10-year survival is shown after an R0 resection.

Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado M, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803CrossRef

Lombard-Bohas C, Mitry E, O’Toole D et al (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217–222. https://doi.org/10.1159/000151562 CrossRefPubMed

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef

Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG (2001) Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9):1295–1300CrossRef

Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ (2008) Changing incidence of pancreatic neoplasms. A 16-year review of nationwide tumor registry. Pancreas 37:134–138CrossRef

Hallet J, Law C, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597CrossRef

Öberg K (2015) Neuroendocrine gastro-enteropancreatic tumors-from eminence based to evidence-based medicine – a Scandinavian view. Scand J Gastroenterol 50(6):727–739. https://doi.org/10.3109/00365521.2015.1033001 CrossRefPubMed

Hallet J, Law CHL, Karanicolas PJ, Saskin R, Liu N, Singh S (2015) Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases. Cancer 121:2214–2221CrossRef

Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Bürk CG, Hoffmann J, Goretzki P, Pape UF, Weitere Vertreter des deutschen NET-Registers (2012) Neuroendocrine tumours of the GI tract--data from the German NET registry. Zentralbl Chir 139(3):276–283. https://doi.org/10.1055/s-0032-1315199 CrossRefPubMed

10.

Klith G, Couvelard A, Perren A et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90:162–166CrossRef

11.

Boninsegna L, Panzuto F, Partelli S (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48:1608–1615CrossRef

12.

Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS) (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401CrossRef

13.

Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762CrossRef

14.

Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, Seventh edn. Wiley-Blackwell, Oxford

15.

Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumours of the digestive system, Fourth edn. International Agency for Research on Cancer (IARC), Lyon

16.

Pape UF, Pascher A, Arsenic R, Ezziddin S, Jann H, Pavel ME, Wiedenmann B (2011) Gastrointestinal neuroendocrine neoplasias: novel individualized therapeutic strategies. Dtsch Med Wochenschr 136(36):1801–1806. https://doi.org/10.1055/s-0031-1286106 CrossRefPubMed

17.

Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, la Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777. https://doi.org/10.1093/jnci/djs208 CrossRefPubMed

18.

Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117(15):3332–3341. https://doi.org/10.1002/cncr.25855 CrossRefPubMed

19.

Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D, Frascati Consensus Conference participants (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 87(1):47–62CrossRef

20.

Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96(2):175–184. https://doi.org/10.1002/bjs.6468 CrossRefPubMed

21.

Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244(3):410–419PubMedPubMedCentral

22.

Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai G, Falconi M (2015) Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology 102:68–76CrossRef

23.

Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R, representatives of 21 German NET Centers (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90:349–363CrossRef

24.

Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors of the digestive system. Lyon, IARC

25.

Sakin A, Tambas M, Secmeler S et al Factors affecting survival in neuroendocrine tumors: a 15-year single center experience. Asian Pac J Cancer Prev 19(12):3597–3603CrossRef

26.

Niederle MB, Hackl M, Kaserer K, Niederle B (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17:909–918CrossRef

27.

Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E (2018) Survival in neuroendocrine neoplasms: a report from a large Norwegian population-based study. Int J Cancer 142(6):1139–1147. https://doi.org/10.1002/ijc.31137 PMid:29082524CrossRefPubMed

28.

Jilesen APJ, van Eijck CHJ, in’t Hof KH et al (2016) Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrein tumor: a systematic review. World J Surg 40:729–748CrossRef

29.

Hill JS, McPhee JT, McDade TP et al (2009) Pancreatic neuroendocrine tumors-the impact of surgical resection on survival. Cancer:741–751

30.

Shafqat H, Ali S, Salhab M et al Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population ation population lation h and colon, surgery is seen as the

Title: Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry
Authors: Nehara Begum
Sebastian Maasberg
Andreas Pascher
Ursula Plöckinger
Thomas M. Gress
Christine Wurst
Frank Weber
Andreas Raffel
Markus Krausch
Katharina Holzer
Detlef K. Bartsch
Thomas J. Musholt
Tobias Keck
Martin Anlauf
Anja Rinke
Ulrich-Frank Pape
Peter E. Goretzki
On behalf of the German NET-Registry
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: Langenbeck's Archives of Surgery / Issue 2/2020
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-020-01868-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry

Abstract

Background

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Comparing the efficacy and safety of laparoscopic and robotic adrenalectomy: a meta-analysis and trial sequential analysis

A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease

A multicenter cohort analysis of laparoscopic hepatic caudate lobe resection

Ligating the rectum with cable tie facilitates rectum transection in laparoscopic anterior resection of rectal cancer

Endoscopic parathyroidectomy using a three-port submental approach

Feasibility and usability of real-time intraoperative quantitative fluorescent-guided perfusion assessment during resection of gastroesophageal junction cancer